ArticleInfectious diseases and therapy2025
Ensitrelvir in Hospitalized Patients with SARS-CoV-2 During the Omicron Epidemic: A Single-Center Observational Study.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug-Drug Interaction Study.Clinical drug investigation · 2026Article
- Ensitrelvir in hospitalized patients with COVID-19 who were moderately to severely immunocompromised: a single-center cohort study.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEnsitrelvir, a novel oral 3C-like protease inhibitor targeting severe acute respiratory syndrome coronavirus 2, has been available in Japan since November 2022. This report presents patient characteristics and treatment outcomes of patients receiving ensitrelvir with comparison to remdesivir during the same period.
methodsA single-center chart review was conducted at Rinku General Medical Center, one of four designated medical institutions for specific infectious diseases in Japan. All hospitalized patients with coronavirus disease 2019 (COVID-19) between November 2022 and August 2024 who received either ensitrelvir or remdesivir in accordance with the on-label dosage and administration were included in the review. Information on patient background, severity of COVID-19, mortality after initiation of either treatment, post-treatment virologic outcomes, and clinical outcomes were collected from electronic records. Day 28 mortality, time to discharge, and time to viral clearance were calculated with and without adjustment using the inverse probability of treatment weighting (IPTW) method.
resultsDuring the study period, 156 patients received ensitrelvir and 337 received remdesivir as initial treatments, with average ages of 76.8 and 75.7 years, respectively. For baseline severity, 24.4% of ensitrelvir recipients and 50.7% of remdesivir recipients had moderate to severe COVID-19. All-cause mortality at day 28 was 1.9% for ensitrelvir and 5.9% for remdesivir and the hazard ratio was 0.32 (95% CI 0.09-1.07). All-cause mortality after IPTW adjustment was 3.8% and 5.7%, respectively, and the hazard ratio was 0.66 (95% CI 0.19-2.29). Time to discharge was shorter with ensitrelvir, and viral clearance was similar between groups.
conclusionEnsitrelvir demonstrated a low day 28 mortality, even among patients with advanced age, immunosuppressive conditions, and moderate to severe COVID-19. These findings may suggest a potential role for ensitrelvir in the treatment of hospitalized patients with COVID-19.
trial registrationThis study was registered in UMIN Clinical Trials Registry (study ID UMIN000056047).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.